CTLA-4 blockade was first evaluated in prostate cancer in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model, where the role of adjunctive CTLA-4 blockade in mice with minimal residual metastatic disease was studied. The gene discussed is CTLA4; the disease is prostate carcinoma.